PMID- 36826713
OWN - NLM
STAT- MEDLINE
DCOM- 20230920
LR  - 20230920
IS  - 1559-0720 (Electronic)
IS  - 0163-4984 (Linking)
VI  - 201
IP  - 11
DP  - 2023 Nov
TI  - Insulin Receptor Substrates Regulation and Clinical Responses Following 
      Vanadium-Enriched Yeast Supplementation in Obese Type 2 Diabetic Patients: a 
      Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
PG  - 5169-5182
LID - 10.1007/s12011-023-03604-4 [doi]
AB  - Increasing evidence suggests that organic vanadium compounds are bioavailable and 
      safe therapeutic agents with insulin-mimetic and insulin-enhancing features. The 
      objective of the current study was to examine the effect of vanadium-enriched 
      yeast (VEY) supplementation on the gene expression level of insulin receptor 
      substrates and clinical manifestations of obese type 2 diabetic mellitus (T2DM) 
      patients. In this randomized, double-blind, placebo-controlled clinical trial, 44 
      obese T2DM patients were randomly allocated into either VEY (0.9 mg/day vanadium 
      pentoxide) or placebo group for 12 weeks. The mRNA expression level of protein 
      tyrosine phosphatase 1B (PTP1B), phosphatase and tensin homolog (PTEN), 
      mitogen-activated protein kinase (MAPK), ribosomal protein S6 kinase (S6K), and 
      nuclear factor kappa-light-chain-enhancer of activated B cells (NFKB) genes in 
      the peripheral blood mononuclear cells, serum levels of metabolic parameters, 
      anthropometric indices, as well as the quality of life, and dietary intake were 
      collected at pre- and post-intervention phases. Analysis of covariance was 
      performed to obtain the corresponding effect size. Results showed that VEY 
      administration significantly decreased anthropometric indices and glycemic 
      parameters and increased insulin sensitivity after adjusting for potential 
      covariates (p < 0.05), in comparison to the placebo group. Additionally, VEY 
      supplementation was significantly effective on MAPK, PTP1B, and NFKB gene 
      expression level, compared to the placebo group. No significant changes were 
      noticed for dietary intake, quality of life, and lipid profile in the VEY group, 
      compared to the placebo group. Overall, VEY supplementation can be considered as 
      a promising safe adjunct therapy for improving anthropometric indices and 
      glycemic parameters in T2DM patients.
CI  - (c) 2023. The Author(s), under exclusive licence to Springer Science+Business 
      Media, LLC, part of Springer Nature.
FAU - Ghalichi, Faezeh
AU  - Ghalichi F
AD  - Faculty of Nutrition and Food Sciences, Department of Clinical Nutrition, Tabriz 
      University of Medical Sciences, Tabriz, Iran.
AD  - Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.
FAU - Saghafi-Asl, Maryam
AU  - Saghafi-Asl M
AD  - Nutrition Research Center, Drug Applied Research Center, Department of Clinical 
      Nutrition, Faculty of Nutrition & Food Sciences, Tabriz University of Medical 
      Sciences, Tabriz, Iran.
FAU - Kafil, Behnam
AU  - Kafil B
AD  - Stem Cell and Regenerative Medicine Institute, Tabriz University of Medical 
      Sciences, Tabriz, Iran.
FAU - Faghfouri, Amir Hossein
AU  - Faghfouri AH
AD  - Maternal and Childhood Obesity Research Center, Urmia University of Medical 
      Sciences, Urmia, Iran.
FAU - Jourshari, Mahtab Rajabi
AU  - Jourshari MR
AD  - Faculty of Nutrition and Food Sciences, Department of Clinical Nutrition, Tabriz 
      University of Medical Sciences, Tabriz, Iran.
FAU - Naserkiadeh, Amin Akbari
AU  - Naserkiadeh AA
AD  - Faculty of Nutrition and Food Sciences, Department of Clinical Nutrition, Tabriz 
      University of Medical Sciences, Tabriz, Iran.
FAU - Ostadrahimi, Alireza
AU  - Ostadrahimi A
AD  - Faculty of Nutrition and Food Sciences, Department of Clinical Nutrition, Tabriz 
      University of Medical Sciences, Tabriz, Iran. ostadrahimi@tbzmed.ac.ir.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20230224
PL  - United States
TA  - Biol Trace Elem Res
JT  - Biological trace element research
JID - 7911509
RN  - 00J9J9XKDE (Vanadium)
RN  - EC 2.7.10.1 (Receptor, Insulin)
RN  - 0 (Blood Glucose)
RN  - 0 (Insulin)
SB  - IM
MH  - Humans
MH  - Vanadium/pharmacology/therapeutic use/metabolism
MH  - Saccharomyces cerevisiae/metabolism
MH  - Receptor, Insulin/metabolism
MH  - Blood Glucose
MH  - Leukocytes, Mononuclear/metabolism
MH  - Quality of Life
MH  - Insulin/metabolism
MH  - *Insulin Resistance
MH  - *Yeast, Dried
MH  - *Diabetes Mellitus, Type 2
MH  - Double-Blind Method
MH  - Dietary Supplements
OTO - NOTNLM
OT  - Diabetes mellitus
OT  - Insulin receptor substrates
OT  - Insulin resistance
OT  - Saccharomyces cerevisiae
OT  - Vanadium
EDAT- 2023/02/25 06:00
MHDA- 2023/09/20 06:42
CRDT- 2023/02/24 11:36
PHST- 2023/02/01 00:00 [received]
PHST- 2023/02/15 00:00 [accepted]
PHST- 2023/09/20 06:42 [medline]
PHST- 2023/02/25 06:00 [pubmed]
PHST- 2023/02/24 11:36 [entrez]
AID - 10.1007/s12011-023-03604-4 [pii]
AID - 10.1007/s12011-023-03604-4 [doi]
PST - ppublish
SO  - Biol Trace Elem Res. 2023 Nov;201(11):5169-5182. doi: 10.1007/s12011-023-03604-4. 
      Epub 2023 Feb 24.